Symposium on Hiemolytic
Disease of the Newborn with Special Reference to ABO Incompatibility Dr C C Bowley (Regional Blood Transfusion Centre, Sheffield)
Some Problems of Organization and Prediction
The antenatal prediction and management of Rhesus hemolytic disease of the newborn is now well understood and reasonably well organized. There are, however, several points which are perhaps not sufficiently appreciated and deserve further consideration.
(1) Selection ofblood samples: The aim should be to test every sample that may yield information of value to the clinician, without performing unnecessary time-and reagent-consuming work. Whilst we all acknowledge that every primigravida should be grouped and that a report should be issued to the medical officer and a blood group card given to the patient for her personal use, the indications for routine repetition of tests are not so well agreed. In our view, such tests, adapted to include a special search for antibodies in the maternal serum, must be performed not only on all known Rhesus-negative multigravidxe, but on all those with a history of past transfusion or of unexplained stillbirths or jaundiced or anaemic babies. From our experience at Sheffield of nearly 600,000 antenatal blood grouping records, and current testing of about 1,700 samples each week, we do not consider it necessary to re-test a known normal A positive woman in each successive pregnancy. Neither is it necessary to test repeatedly a normal Rhesus-negative mother during her first pregnancy in the absence of transfusion history, &c. There is also much muddled thinking about testing husbands. There is no point in sampling and testing a husband because his wife is found to bea-normal Rhem,&negative woman. Eighty-five times out of every hundred he will have to be told that he is Rhesus positive. With the partial enlightenment that the public now has (from television and popular magazines) this causes quite unnecessary concern. It is advisable rather to tell the expectant father that nothing is required of him because everything is so normal. If (and when) maternal antibodies do develop (i.e. in only about one in ten of such matings) the father's blood can be tested, at which time Rhesus genotyping, in addition to ABO grouping, is imperative. The former certainly cannot be undertaken as a routine for normal husbands ofnormal wives.
(2) Place of testing: These tests should be performed only in laboratories that at all times command adequate panels of test cellsto ensure that all the clinically significant antigens, such as Kell, S, Duffy and Kidd, in addition to the Rhesus antigens, are represented. The same laboratory need not necessarily possess all the facilities for the final, complete identification of antibodies so detected, although there are obvious advantages to both patient and clinician when, as in the Sheffield region, this is the case. The best results are not obtained by every antenatal clinic having its blood grouping performed locally, and a degree ofcentralization of this work is desirable.
(3) Organization of testing: The organization should be such that the antenatal identification of an immune antibody of clinical significance ensures delivery in an approved hospital unit that not only can cope with any obstetric abnormality, but possesses the necessary laboratory facilities and clinical staff for immediate investigation of the child, selection of compatible blood, and performance of exchange transfusion when necessary. These units need to be so sited as to be geographically convenient for patients and their visitors, but sufficiently few for their staff to become experienced and skilled in the management of these cases and in the technique of exchange transfusion. Perhaps a minimum of fifty such transfusions a year in each unit might be cons dered not unreasonable. At such centres the Transfusion Service should endeavour to maintain constant stocks of maximum survival group O and group A Rhesus-negative blood. We do this, and the laboratories concerned, knowing both the father's and the mother's ABO group, prepare compatible blood by cross-matching to the maternal serum before the infant is born. They can then without further delay provide from stock homologous group blood for transfusion to nine out of ten affected infants. This organization therefore p-e umes that, although identification of antibodies is properly the work of a reference laboratory, the prompt investigation of the newborn child is very much the province of the local patho'ogist. In our region all the staff in the hospital laboratories responsible for this work have been trained at the Transfus'on Centre, and we are convinced that this is well worth while.
(4) Antibody titres: The obstetricians and paediatricians in the Sheffield, Rotherham and Barnsley area, basing their treatment of sensitized mothers on all available information except the antibody titre, which was not known to them, achieved a 14 % total foetal wastage (including stillbirths and intra-uterine deaths) on 264 foetuses over a twoyear period (Bowley 1962) . The antibody titres in these cases were known to the Transfusion Centre only. The series is now continuing for a further two years with the antibody titres reported to the clinicians in the first and second trimesters and fortnightly from the twenty-eighth week. Already we are aware that a high antibody titre is not necessarily significant apart from the first affected pregnancy. With a history of a previously affected child a high titre can be associated with a Rhesusnegative feetus. In contrast, it seems probable that a low antibody titre is generally a reliable indication of a mildly affected infant which may not even require treatment. Certainly in a first affected pregnancy, a titre which stays low is of more clinical value than one which rises. Special mention must also be made of the not infrequent case where a first affected foetus in only a second pregnancy is lost through intra-uterine or neonatal death. Such cases are usually associated with a lack of ABO incompatibility between mother and father and the presence of an unfavourable paternal genotype, e.g. R2R2. At one stage in our investigation we had 5 such cases among 81 first affected babies, and although the anti-humanglobulin titre in 3 of these was 80, 160 and 320, in the other two it never rose above 20. Exceptions like these, occurring in both directions, cause considerable concern and make us wonder if the significance of antibody titres has in fact received sufficient consideration, or whether they may not have been accepted a little too readily. Some recent comments have led us to consider whether the apparent acceptance of antibody titres by some pediatricians might be accounted for by a lack of transparency with the obstetricians, resulting in a comparative ignorance of the stillbirths and intra-uterine deaths which never reach them.
(5) The interpretation of a positive anti-humanglobulin test: Althoug'hi in this context a positive test is generally indicative of hemolytic disease, it is not infallibly so. A positive result unsuppor.ed by other laboratory and clinical evidence should lead to a repetition of the test on both faetal and maternal samples. In a number of cases both will be positive, usually owing to a Dacie type of cold incomplete antibody. Conversely, hemolytic disease may be present with a negative anti-humang'obulin test.
ABO Hamolytic Disease
(1) Incidence andpresentation: Being virtually confined to 0 mothers with A or B infants, the maximum theoretical incidence in Caucasians would be about 1:5 of all infants born to 0 mothers. However, in many cases the condition is subclinical and of necessity remains undetected. Mollison (1961) suggests a minimum incidence of 1:150 births, i.e. more frequent than Rhesus incompatibility, and indeed Allen & Diamond (1957) suggest that it occurs twice as often as Rh hmemolytic disease. We would certainly wish to stress that ABO hemolytic disease is not a rare condition. In our experience, Mollison's suggestion that only 1:3,000 actually requires treatment is probably an under-estimate due to missed diagnosis. Fortunately this condition less often requires treatment than Rhesus disease, and transfusion therapy, when required, is not generally so urgent as for icterus gravis due to Rhesus incompatibility; but some cases do demand an urgent replacement transfusion. The usual clinical presentation of these cases can be explained by postulating a much slower hvemolytic process than with Rhesus disease. Jaundice is slower to develop, generally less severe, and indeed may not be noticed, may be classified as 'physiological' or may be absent. Anaemia almost always develops, however, so that in many cases the presenting sign is anamia at 2 to 3 weeks of age. Until all such cases are recognized and investigated, the true incidence of the condition must remain in doubt. Occasionally the process may be rapid and indistinguishable clinically from Rhesus disease. It might be of interest to consider the suggestion that the immune type of anti-A responsible for this condition is generally, but not invariably, a complement-consuming antibody and that the speed of the hemolysis in the infant may depend on this, coupled with a lack or defect of the complement of the infant at birth, and that the acute case, indistinguishable from icterus gravis, is associated with a non-complement-consuming antibody comparable with anti-D.
It is well known that the condition can occur in a first pregnancy and that a subsequent child of the same ABO group will not necessarily be affected at all. But we are also aware of an increasing number of cases where one or even two subsequent children have been affected by the same mechanism and have required treatment. There is, furthermore, growing evidence to suggest that our evaluation of this disease in Caucasian races may well need modification for negroes, in whom ABO hkmolytic diEease seems to be more severe.
(2) The significance of antenatal laboratory findings: We may assume that it is possible to demonstrate in the maternal serum the presence of what, for want of a better name, may be called 'an immune form of anti-A (or B)'. Unfortunately there are many methods for detecting this, all inconclusive and with no certainty that each detects the same thing. However, we generally accept as diagnostic the demonstration of one or more of the following: (a) The presence of a lysin active with complement against fresh adult Al cells at body temperature. (b) Difficulty or inability to neutralize the maternal serum complete antibody by the addition of the appropriate blood group substance. (c) The presence of a thermostable form of incomplete antibody. (d) A high titre of incomplete antibody after partial neutralization, coupled with inversion of the thermal optimum.
The significance of such a set oF results d-ring pregnancy is, unfortunately, almost nil, except that the possibility of hemolytic disease exists if the father's group is incompatible with that of the mother. The tests are so time-consuming and inconclusive that they are impracticable for normal antenatal work and, in the absence of a significant past history, will only be performed if indicated after delivery. Unlike Rhesus disease, the antenatal prediction of ABO hemolytic disease with any degree of certainty is therefore impossible as yet, although the recent work of Tovey et al. (1962) offers some hope that the test using AP (Group A pig) cells may develop into an answer to this problem.
(3) What can be done after delivery? The absolute diagnosis of ABO hemolytic disease cannot be made either clinically or serologically. One can only use each set of results to confirm the other, and treat the child accordingly. Having confirmed the existence of ABO incompatibility between mother and child, the presence of spherocytosis and increased red cell fragility in the infant is suggestive but not essential. In the first few days, even in the presence of quite deep jaundice, antemia is not generally obvious. Hemoglobin levels below 10 g/100 ml are rare, and values of 12 to 14 g/100 ml in clinically affected children are common. The direct anti-human-globulin test on the baby's cells is typically negative. A strongly positive result may even be the first indication that the condition is in fact due to some other antigen/antibody reaction. Nevertheless, the Coombs negative cells of affected babies can sometimes be eluted to yield a form of anti-A which can be transferred to fresh adult A1 cells to give a positive anti-human-globulin reaction. One other possibly associated pitfall requires explanation. With Rhesus hemolytic disease, testing the mother's serum (suitably absorbed if necessary) by appropriate technique against the baby's cells, is the critical test. In ABO incompatibility this invariably gives a negative result. Possibly this is due to the fact that an affected Group A infant's cells always group as A2, i.e. are not agg'utinated by anti-A1, although they can in fact, by family study or after six months' survival, be shown to be A1. The examination of the maternal serum, however, demands the use of fresh A1 cells if positive results are to be obtained.
In conclusion, I quote from Zuelzer & Cohen (1957) :
'ABO hemolytic disease is no myth, but a reality which becomes frightening, since it may, if neglected, end much like Rh hemolytic disease with an encephalopathy, kernicterus, with subsequent death or development of grave neurological sequels. It is essential, therefore, to be on guard against such an event and to be familiar with the practical and theoretical aspects of the condition. Its very danger lies in its apparent mildness when regarded as a hvmolytic process, in its deceptive blending into the bilirubin-tinted landscape of newborn physiology.'
